

Joaquim Ferreira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9072400/publications.pdf>

Version: 2024-02-01

324
papers

12,989
citations

31976

53
h-index

32842

100
g-index

335
all docs

335
docs citations

335
times ranked

13517
citing authors

#	ARTICLE	IF	CITATIONS
1	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. <i>Lancet Neurology</i> , The, 2008, 7, 583-590.	10.2	1,340
2	How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. <i>Movement Disorders</i> , 2010, 25, 534-541.	3.9	728
3	A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. <i>Lancet</i> , The, 2005, 365, 412-415.	13.7	449
4	ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. <i>Neurology</i> , 2007, 68, 1557-1562.	1.1	312
5	Summary of the recommendations of the <sc>EFNS</sc>/<sc>MDS</sc>â€<sc>ES</sc> review on therapeutic management of <sc>P</sc>arkinson's disease. <i>European Journal of Neurology</i> , 2013, 20, 5-15.	3.3	290
6	Quantitative wearable sensors for objective assessment of Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 1628-1637.	3.9	287
7	Limitations of current Parkinson's disease therapy. <i>Annals of Neurology</i> , 2003, 53, S3-S15.	5.3	250
8	Convergence of miRNA Expression Profiling, Î±-Synuclein Interacton and GWAS in Parkinson's Disease. <i>PLoS ONE</i> , 2011, 6, e25443.	2.5	235
9	DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type Aâ€”Dysport and Botoxâ€”assuming a ratio of 4:1. <i>Movement Disorders</i> , 1997, 12, 1013-1018.	3.9	220
10	Sleep attacks and Parkinson's disease treatment. <i>Lancet</i> , The, 2000, 355, 1333-1334.	13.7	220
11	Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. <i>Lancet Neurology</i> , The, 2016, 15, 154-165.	10.2	219
12	Scales to assess sleep impairment in Parkinson's disease: Critique and recommendations. <i>Movement Disorders</i> , 2010, 25, 2704-2716.	3.9	214
13	Late-stage Parkinson disease. <i>Nature Reviews Neurology</i> , 2012, 8, 435-442.	10.1	183
14	Endovascular treatment versus medical care alone for ischaemic stroke: systematic review and meta-analysis. <i>BMJ</i> , The, 2016, 353, i1754.	6.0	157
15	A systematic review of the characteristics and validity of monitoring technologies to assess Parkinsonâ€™s disease. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2016, 13, 24.	4.6	155
16	Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. <i>European Journal of Human Genetics</i> , 2006, 14, 322-331.	2.8	152
17	Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: A systematic review. <i>Parkinsonism and Related Disorders</i> , 2010, 16, 237-242.	2.2	150
18	Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations. <i>JAMA Neurology</i> , 2017, 74, 197.	9.0	146

#	ARTICLE	IF	CITATIONS
19	Dopamine agonist therapy in early Parkinson's disease. The Cochrane Library, 2008, , CD006564.	2.8	120
20	New methods for the assessment of Parkinson's disease (2005 to 2015): A systematic review. Movement Disorders, 2016, 31, 1283-1292.	3.9	119
21	Efficacy and safety of sirolimus in the treatment of vascular anomalies: A systematic review. Journal of Vascular Surgery, 2020, 71, 318-327.	1.1	117
22	Clinical comparability of marketed formulations of botulinum toxin. Movement Disorders, 2004, 19, S129-S136.	3.9	111
23	MDS evidence-based review of treatments for essential tremor. Movement Disorders, 2019, 34, 950-958.	3.9	108
24	Late-stage Parkinson's disease: the Barcelona and Lisbon cohort. Journal of Neurology, 2010, 257, 1524-1532.	3.6	106
25	Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart, 2015, 101, 1204-1211.	2.9	106
26	Safety of Chiropractic Interventions. Spine, 2009, 34, E405-E413.	2.0	103
27	LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study. Lancet Neurology, The, 2018, 17, 597-608.	10.2	101
28	Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity. Neurology, 2017, 88, 1321-1328.	1.1	99
29	International Guidelines for the Treatment of Huntington's Disease. Frontiers in Neurology, 2019, 10, 710.	2.4	98
30	New treatments for levodopa-induced motor complications. Movement Disorders, 2015, 30, 1451-1460.	3.9	95
31	Therapeutic interventions for symptomatic treatment in Huntington's disease. The Cochrane Library, 2009, , CD006456.	2.8	91
32	Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart, 2014, 100, 550-556.	2.9	91
33	Substantia nigra neuromelanin magnetic resonance imaging in <i>de novo</i> Parkinson's disease patients. European Journal of Neurology, 2015, 22, 540-546.	3.3	90
34	Sleep Attacks and Antiparkinsonian Drugs: A Pilot Prospective Pharmacoepidemiologic Study. Clinical Neuropharmacology, 2001, 24, 181-183.	0.7	85
35	Hyposmia in G2019S LRRK2-related parkinsonism. Neurology, 2008, 71, 1021-1026.	1.1	82
36	Sleep disruption, daytime somnolence and 'sleep attacks' in Parkinson's disease: a clinical survey in PD patients and age-matched healthy volunteers. European Journal of Neurology, 2006, 13, 209-214.	3.3	80

#	ARTICLE	IF	CITATIONS
37	Neutralizing Antibody and Botulinum Toxin Therapy: A Systematic Review and Meta-analysis. <i>Neurotoxicity Research</i> , 2016, 29, 105-117.	2.7	79
38	Posttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson's disease. <i>Scientific Reports</i> , 2017, 7, 13713.	3.3	79
39	Validation of a Step Detection Algorithm during Straight Walking and Turning in Patients with Parkinson's Disease and Older Adults Using an Inertial Measurement Unit at the Lower Back. <i>Frontiers in Neurology</i> , 2017, 8, 457.	2.4	79
40	High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal. <i>Movement Disorders</i> , 2007, 22, 1194-1201.	3.9	76
41	Caffeine does not increase the risk of atrial fibrillation: a systematic review and meta-analysis of observational studies. <i>Heart</i> , 2013, 99, 1383-1389.	2.9	75
42	Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson's disease: Systematic review and meta-analysis. <i>Parkinsonism and Related Disorders</i> , 2016, 27, 25-34.	2.2	74
43	Serum lipid alterations in GBA-associated Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 44, 58-65.	2.2	73
44	Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine. <i>Movement Disorders</i> , 2018, 33, 1528-1539.	3.9	73
45	A critique of the second consensus criteria for multiple system atrophy. <i>Movement Disorders</i> , 2019, 34, 975-984.	3.9	73
46	Effect of ropinirole on sleep onset: A randomized, placebo-controlled study in healthy volunteers. <i>Neurology</i> , 2002, 58, 460-462.	1.1	71
47	Quantitative home-based assessment of Parkinson's symptoms: The SENSE-PARK feasibility and usability study. <i>BMC Neurology</i> , 2015, 15, 89.	1.8	71
48	Substantia nigra neuromelanin MR imaging differentiates essential tremor from Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 953-959.	3.9	69
49	Survival, Mortality, Causes and Places of Death in a European Huntington's Disease Prospective Cohort. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 737-742.	1.5	65
50	Clinical Practice: Evidence-Based Recommendations for the Treatment of Cervical Dystonia with Botulinum Toxin. <i>Frontiers in Neurology</i> , 2017, 8, 35.	2.4	63
51	Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease. <i>European Journal of Neurology</i> , 2016, 23, 368-374.	3.3	62
52	Do patients with late-stage Parkinson's disease still respond to levodopa?. <i>Parkinsonism and Related Disorders</i> , 2016, 26, 10-16.	2.2	60
53	Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease. <i>European Journal of Neurology</i> , 2015, 22, 815.	3.3	58
54	Clinical trials in palliative care: a systematic review of their methodological characteristics and of the quality of their reporting. <i>BMC Palliative Care</i> , 2017, 16, 10.	1.8	56

#	ARTICLE	IF	CITATIONS
55	Botulinum toxin type A therapy for blepharospasm. The Cochrane Library, 2004, , CD004900.	2.8	52
56	The Placebo Response in Studies of Acute Migraine. Journal of Pediatrics, 2008, 152, 527-533.e1.	1.8	52
57	Therapeutic interventions for disease progression in Huntington's disease. The Cochrane Library, 2009, , CD006455.	2.8	52
58	Botulinum toxin type-B improves sialorrhea and quality of life in bulbar onset amyotrophic lateral sclerosis. Journal of Neurology, 2008, 255, 545-550.	3.6	51
59	Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants. Alimentary Pharmacology and Therapeutics, 2015, 42, 1239-1249.	3.7	51
60	An evidence-based approach in the treatment of Huntington's disease. Parkinsonism and Related Disorders, 2012, 18, 316-320.	2.2	50
61	Fifteen Years of Clinical Trials in Huntington's Disease: A Very Low Clinical Drug Development Success Rate. Journal of Huntington's Disease, 2017, 6, 157-163.	1.9	50
62	Speech and Voice Response to a Levodopa Challenge in Late-Stage Parkinson's Disease. Frontiers in Neurology, 2017, 8, 432.	2.4	50
63	European Academy of Neurology/Movement Disorder Society European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies. Movement Disorders, 2022, 37, 1360-1374.	3.9	49
64	Tetrabenazine Versus Deutetrabenazine for Huntington's Disease: Twins or Distant Cousins?. Movement Disorders Clinical Practice, 2017, 4, 582-585.	1.5	48
65	Botulinum toxin type A therapy for hemifacial spasm. The Cochrane Library, 2005, , CD004899.	2.8	47
66	Physical Activity, Exercise, and Physiotherapy in Parkinson's Disease: Defining the Concepts. Movement Disorders Clinical Practice, 2020, 7, 7-15.	1.5	47
67	Putaminal petechial haemorrhage as the cause of non-ketotic hyperglycaemic chorea: a neuropathological case correlated with MRI findings. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 549-550.	1.9	46
68	Associated movement disorders in orthostatic tremor. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 725-729.	1.9	46
69	Placebo and nocebo responses in restless legs syndrome. Neurology, 2017, 88, 2216-2224.	1.1	46
70	Recommendations for the Organization of Multidisciplinary Clinical Care Teams in Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, 1087-1098.	2.8	46
71	Clinical pharmacology review of safinamide for the treatment of Parkinson's disease. Neurodegenerative Disease Management, 2015, 5, 481-496.	2.2	45
72	Levodopa monotherapy can induce "sleep attacks" in Parkinson's disease patients. Journal of Neurology, 2001, 248, 426-427.	3.6	44

#	ARTICLE	IF	CITATIONS
73	Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations. <i>Movement Disorders</i> , 2016, 31, 1466-1478.	3.9	44
74	Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test. <i>Parkinsonism and Related Disorders</i> , 2017, 39, 37-43.	2.2	44
75	Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2017, 7, 491-501.	2.8	44
76	Deep brain stimulation for dystonia. <i>The Cochrane Library</i> , 2020, 2020, CD012405.	2.8	44
77	Skin cancer and Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 139-148.	3.9	43
78	Risk of Developing Parkinson Disease in Bipolar Disorder. <i>JAMA Neurology</i> , 2020, 77, 192.	9.0	42
79	Paralytic shellfish poisoning due to ingestion of <i>Gymnodinium catenatum</i> contaminated cockles – Application of the AOAC HPLC Official Method. <i>Toxicon</i> , 2012, 59, 558-566.	1.6	41
80	Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. <i>European Journal of Neurology</i> , 2019, 26, 953-960.	3.3	41
81	Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. <i>Neurology</i> , 2018, 90, e1849-e1857.	1.1	40
82	What is Functional Mobility Applied to Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , 2018, 8, 121-130.	2.8	39
83	Influenza vaccination in patients with heart failure: a systematic review and meta-analysis of observational studies. <i>Heart</i> , 2020, 106, 350-357.	2.9	39
84	Dementia and severity of parkinsonism determines the handicap of patients in late-stage Parkinson's disease: the Barcelona~Lisbon cohort. <i>European Journal of Neurology</i> , 2015, 22, 305-312.	3.3	38
85	Gene Expression Differences in Peripheral Blood of Parkinson's Disease Patients with Distinct Progression Profiles. <i>PLoS ONE</i> , 2016, 11, e0157852.	2.5	36
86	Botulinum toxin type B for cervical dystonia. <i>The Cochrane Library</i> , 2016, 2016, CD004315.	2.8	36
87	Continuous leg dyskinesia assessment in Parkinson's disease – clinical validity and ecological effect. <i>Parkinsonism and Related Disorders</i> , 2016, 26, 41-46.	2.2	36
88	Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: A randomized-controlled trial. <i>Movement Disorders</i> , 2016, 31, 1649-1657.	3.9	35
89	Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial. <i>Movement Disorders</i> , 2015, 30, 1426-1429.	3.9	33
90	Does Parkinson's disease increase the risk of cardiovascular events? A systematic review and meta-analysis. <i>European Journal of Neurology</i> , 2020, 27, 288-296.	3.3	32

#	ARTICLE	IF	CITATIONS
91	Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 466-467.	2.2	31
92	Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. <i>The Cochrane Library</i> , 2016, 2016, CD004314.	2.8	31
93	Effects of Nebicapone on Levodopa Pharmacokinetics, Catechol-O-methyltransferase Activity, and Motor Fluctuations in Patients with Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2008, 31, 2-18.	0.7	30
94	Huntington's Disease Clinical Trials Corner: June 2019. <i>Journal of Huntington's Disease</i> , 2019, 8, 363-371.	1.9	30
95	Risk of Substantial Intraocular Bleeding With Novel Oral Anticoagulants. <i>JAMA Ophthalmology</i> , 2015, 133, 834.	2.5	29
96	Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-methyltransferase Activity and Motor Response in Patients With Parkinson Disease. <i>Clinical Pharmacology in Drug Development</i> , 2016, 5, 232-240.	1.6	29
97	Circulating Inflammatory miRNAs Associated with Parkinson's Disease Pathophysiology. <i>Biomolecules</i> , 2020, 10, 945.	4.0	29
98	Oral Anticoagulation for Pulmonary Arterial Hypertension: Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2014, 30, 879-887.	1.7	28
99	A Perspective on Wearable Sensor Measurements and Data Science for Parkinson's Disease. <i>Frontiers in Neurology</i> , 2017, 8, 677.	2.4	28
100	Adjunctive Therapies in Parkinson's Disease: How to Choose the Best Treatment Strategy Approach. <i>Drugs and Aging</i> , 2018, 35, 1041-1054.	2.7	28
101	Validation of a Lower Back Wearable-Based Sit-to-Stand and Stand-to-Sit Algorithm for Patients With Parkinson's Disease and Older Adults in a Home-Like Environment. <i>Frontiers in Neurology</i> , 2018, 9, 652.	2.4	28
102	Are genetic and idiopathic forms of Parkinson's disease the same disease?. <i>Journal of Neurochemistry</i> , 2020, 152, 515-522.	3.9	28
103	Measurement Instruments to Assess Functional Mobility in Parkinson's Disease: A Systematic Review. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 129-139.	1.5	28
104	A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n=64) study of naftazone in Parkinson's disease. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 557-564.	1.9	27
105	Participatory Design in Parkinson's Research with Focus on the Symptomatic Domains to be Measured. <i>Journal of Parkinson's Disease</i> , 2015, 5, 187-196.	2.8	27
106	Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 111-117.	1.5	27
107	Study protocol: Care of Late-Stage Parkinsonism (CLaSP): a longitudinal cohort study. <i>BMC Neurology</i> , 2018, 18, 185.	1.8	27
108	The association of influenza infection and vaccine with myocardial infarction: systematic review and meta-analysis of self-controlled case series. <i>Expert Review of Vaccines</i> , 2019, 18, 1211-1217.	4.4	27

#	ARTICLE	IF	CITATIONS
109	Moving towards home-based community-centred integrated care in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 21-26.	2.2	27
110	The impact of SSRIs on mortality and cardiovascular events in patients with coronary artery disease and depression: systematic review and meta-analysis. <i>Clinical Research in Cardiology</i> , 2021, 110, 183-193.	3.3	27
111	The European Physiotherapy Guideline for Parkinson's Disease: Implications for Neurologists. <i>Journal of Parkinson's Disease</i> , 2018, 8, 499-502.	2.8	27
112	What motivates Parkinson's disease patients to enter clinical trials?. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 667-671.	2.2	26
113	Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 111-115.	2.2	26
114	Algorithm for Turning Detection and Analysis Validated under Home-Like Conditions in Patients with Parkinson's Disease and Older Adults using a 6 Degree-of-Freedom Inertial Measurement Unit at the Lower Back. <i>Frontiers in Neurology</i> , 2017, 8, 135.	2.4	26
115	Dysphagia predicts poor outcome in late-stage Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 73-81.	2.2	26
116	Eslicarbazepine acetate: a new option for the treatment of focal epilepsy. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 221-229.	4.1	25
117	Immunogenicity and Long-Term Efficacy of Botulinum Toxin Type B in the Treatment of Cervical Dystonia. <i>Clinical Neuropharmacology</i> , 2012, 35, 215-223.	0.7	25
118	Safety Profile of Opicapone in the Management of Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2019, 9, 733-740.	2.8	25
119	Levodopa/carbidopa intestinal gel infusion and weight loss in Parkinson's disease. <i>European Journal of Neurology</i> , 2019, 26, 490-496.	3.3	25
120	The late stage of Parkinson's "results of a large multinational study on motor and non-motor complications. <i>Parkinsonism and Related Disorders</i> , 2020, 75, 91-96.	2.2	25
121	Prescribing patterns of antiparkinsonian agents in Europe. <i>Movement Disorders</i> , 2010, 25, 1053-1060.	3.9	24
122	Cognitive performance in aphasia due to stroke: a systematic review. <i>International Journal on Disability and Human Development</i> , 2017, 16, .	0.2	24
123	Lack of evidence for a role of genetic variation in TMEM230 in the risk for Parkinson's disease in the Caucasian population. <i>Neurobiology of Aging</i> , 2017, 50, 167.e11-167.e13.	3.1	24
124	The Prevalence and Determinants of Neuropsychiatric Symptoms in Late-Stage Parkinsonism. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 531-542.	1.5	24
125	The management of cervical dystonia. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 129-140.	1.8	23
126	The Psychometric Properties of the Voice Handicap Index in People With Parkinson's Disease. <i>Journal of Voice</i> , 2017, 31, 258.e13-258.e18.	1.5	23

#	ARTICLE	IF	CITATIONS
127	Morphine in acute coronary syndrome: systematic review and meta-analysis. <i>BMJ Open</i> , 2019, 9, e025232.	1.9	23
128	Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 100-106.	2.2	23
129	Botulinum toxin type A therapy for cervical dystonia. <i>The Cochrane Library</i> , 2020, 2020, CD003633.	2.8	23
130	Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 97-106.	4.0	23
131	GIGYF2 mutations are not a frequent cause of familial Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 703-705.	2.2	22
132	STN-DBS does not change emotion recognition in advanced Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 166-169.	2.2	22
133	Risk of renal failure with the non-vitamin K antagonist oral anticoagulants: systematic review and meta-analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 757-764.	1.9	22
134	The launch of opicapone for Parkinson's disease: negatives versus positives. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 331-337.	2.4	22
135	European Academy of Neurology/Movement Disorder Society -European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies. <i>European Journal of Neurology</i> , 2022, 29, 2580-2595.	3.3	22
136	A Double-blind, Randomized, Placebo and Active-controlled Study of Nebicapone for the Treatment of Motor Fluctuations in Parkinson's Disease. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 337-347.	3.9	21
137	Placebo and nocebo responses in other movement disorders besides Parkinson's disease: How much do we know?. <i>Movement Disorders</i> , 2018, 33, 1228-1235.	3.9	21
138	Temporal stability of the Unified Dyskinesia Rating Scale. <i>Movement Disorders</i> , 2011, 26, 2556-2559.	3.9	20
139	An exome study of Parkinson's disease in Sardinia, a Mediterranean genetic isolate. <i>Neurogenetics</i> , 2015, 16, 55-64.	1.4	20
140	Twelve-week sensor assessment in Parkinson's disease: Impact on quality of life. <i>Movement Disorders</i> , 2016, 31, 1337-1338.	3.9	20
141	Chiropractic manipulation: Reasons for concern?. <i>Clinical Neurology and Neurosurgery</i> , 2007, 109, 922-925.	1.4	19
142	Branded Versus Generic Clopidogrel in Cardiovascular Diseases. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 61, 277-282.	1.9	19
143	Espresso Coffee for the Treatment of Somnolence in Parkinson's Disease: Results of n-of-1 Trials. <i>Frontiers in Neurology</i> , 2016, 7, 27.	2.4	19
144	Motor, cognitive and mobility deficits in 1000 geriatric patients: protocol of a quantitative observational study before and after routine clinical geriatric treatment - the ComOn-study. <i>BMC Geriatrics</i> , 2020, 20, 45.	2.7	19

#	ARTICLE	IF	CITATIONS
145	An <scp>MDS</scp> Evidence-Based Review on Treatments for Huntington's Disease. <i>Movement Disorders</i> , 2022, 37, 25-35.	3.9	19
146	Frequency of dementia in Parkinson's disease: A systematic review and meta-analysis. <i>Journal of the Neurological Sciences</i> , 2022, 432, 120077.	0.6	19
147	Skin cancers and precancerous lesions in Parkinson's disease patients. <i>Movement Disorders</i> , 2007, 22, 1471-1475.	3.9	18
148	Treatment options for non-motor symptoms in late-stage Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 523-535.	1.8	18
149	Acute response of non-motor symptoms to subthalamic deep brain stimulation in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2017, 41, 113-117.	2.2	18
150	Nocebo response in Parkinson's disease: A systematic review and meta-analysis. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 13-19.	2.2	18
151	Caregiver Burden in Late-Stage Parkinsonism and Its Associations. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2022, 35, 110-120.	2.3	18
152	miR-335 Targets LRRK2 and Mitigates Inflammation in Parkinson's Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 661461.	3.7	18
153	Moving towards Integrated and Personalized Care in Parkinson's Disease: A Framework Proposal for Training Parkinson Nurses. <i>Journal of Personalized Medicine</i> , 2021, 11, 623.	2.5	18
154	COMT Inhibitors in the Management of Parkinson's Disease. <i>CNS Drugs</i> , 2022, 36, 261-282.	5.9	18
155	Clinical pharmacology review of opicapone for the treatment of Parkinson's disease. <i>Neurodegenerative Disease Management</i> , 2016, 6, 349-362.	2.2	17
156	Are there effective interventions to prevent hospital-acquired Legionnaires' disease or to reduce environmental reservoirs of Legionella in hospitals? A systematic review. <i>American Journal of Infection Control</i> , 2016, 44, e183-e188.	2.3	17
157	Advanced Parkinson disease patients have impairment in prosody processing. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2016, 38, 208-216.	1.3	17
158	Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 1019-1033.	2.8	17
159	Prevalência da anticoagulação oral em doentes com fibrilhação auricular em Portugal: revisão sistemática e meta-análise de estudos observacionais. <i>Revista Portuguesa De Cardiologia</i> , 2014, 33, 555-560.	0.5	16
160	Subthalamic deep brain stimulation effects on odor identification in Parkinson's disease. <i>European Journal of Neurology</i> , 2015, 22, 207-210.	3.3	16
161	Dysarthria in individuals with Parkinson's disease: a protocol for a binational, cross-sectional, case-controlled study in French and European Portuguese (FraLusoPark). <i>BMJ Open</i> , 2016, 6, e012885.	1.9	16
162	Implementation of a Community-Based Exercise Program for Parkinson Patients: Using Boxing as an Example. <i>Journal of Parkinson's Disease</i> , 2019, 9, 615-623.	2.8	16

#	ARTICLE	IF	CITATIONS
163	Factors Associated with Health-Related Quality of Life in Late-Stage Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 563-570.	1.5	16
164	Frenchay dysarthria assessment (FDA-2) in Parkinson's disease: cross-cultural adaptation and psychometric properties of the European Portuguese version. <i>Journal of Neurology</i> , 2017, 264, 21-31.	3.6	15
165	A distinct neuromelanin magnetic resonance imaging pattern in parkinsonian multiple system atrophy. <i>BMC Neurology</i> , 2020, 20, 432.	1.8	15
166	Clinical Parameters and Tools for Home-Based Assessment of Parkinson's Disease: Results from a Delphi study. <i>Journal of Parkinson's Disease</i> , 2015, 5, 281-290.	2.8	14
167	“Gunslinger” gait: a new cause of unilaterally reduced arm swing. <i>BMJ, The</i> , 2015, 351, h6141.	6.0	14
168	How safe is acetaminophen use in patients treated with vitamin K antagonists? A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2015, 135, 58-61.	1.7	14
169	Mutations in TMEM230 are not a common cause of Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 302-304.	3.9	14
170	Parkinson's Disease and Fabry Disease: Clinical, Biochemical and Neuroimaging Analysis of Three Pedigrees. <i>Journal of Parkinson's Disease</i> , 2020, 10, 141-152.	2.8	14
171	Safety of coffee consumption after myocardial infarction: A systematic review and meta-analysis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 2146-2158.	2.6	14
172	Challenges and Perspectives in the Management of Late-Stage Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, S75-S83.	2.8	14
173	Satisfaction of Patients with Nonvitamin K Anticoagulants Compared to Vitamin K Antagonists: a Systematic Review and Meta-analysis. <i>Thrombosis and Haemostasis</i> , 2021, 121, 366-382.	3.4	14
174	Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia. <i>Functional Neurology</i> , 2012, 27, 225-30.	1.3	14
175	Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease. <i>Current Opinion in Neurology</i> , 2000, 13, 431-436.	3.6	13
176	Quantitative Analysis Versus Visual Assessment of Neuromelanin MR Imaging for the Diagnosis of Parkinson's disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 561-567.	2.8	13
177	Palliative Care for Patients and Families With Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 475-509.	2.0	13
178	Meta-research metrics matter: letter regarding article “indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease”. <i>Journal of Clinical Movement Disorders</i> , 2017, 4, 19.	2.2	13
179	Risk of drowning in people with Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1507-1508.	3.9	13
180	Botulinum toxin type A therapy for blepharospasm. <i>The Cochrane Library</i> , 2020, 2020, CD004900.	2.8	13

#	ARTICLE	IF	CITATIONS
181	A Modified Progressive Supranuclear Palsy Rating Scale. <i>Movement Disorders</i> , 2021, 36, 1203-1215.	3.9	13
182	Recovery after copper-deficiency myeloneuropathy in Wilson's disease. <i>Journal of Neurology</i> , 2013, 260, 1917-1918.	3.6	12
183	Thromboembolic risk in the initiation, switch and interruption/re-initiation of oral anticoagulants: Do newcomers improve outcomes? Insights from a meta-analysis of RCTs. <i>International Journal of Cardiology</i> , 2014, 177, 117-119.	1.7	12
184	Management of dystonia in Europe: a survey of the European network for the study of the dystonia syndromes. <i>European Journal of Neurology</i> , 2016, 23, 772-779.	3.3	12
185	Opicapone for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 445-453.	1.8	12
186	New perspectives on study designs for evaluating neuroprotection in Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1365-1370.	3.9	12
187	Why Palliative Care Applies to Parkinson's Disease. <i>Movement Disorders</i> , 2018, 33, 750-753.	3.9	12
188	Aspirin in the primary prevention of cardiovascular disease on diabetic patients: Systematic review and meta-analysis. <i>Primary Care Diabetes</i> , 2020, 14, 213-221.	1.8	12
189	Droling rating scales in Parkinson's disease: A systematic review. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 173-180.	2.2	12
190	Current and Future Therapeutic Strategies for Parkinson's Disease. <i>Current Pharmaceutical Design</i> , 2009, 15, 3968-3976.	1.9	11
191	ADAGIO trial hints that rasagiline slows disease progression. <i>Nature Reviews Neurology</i> , 2010, 6, 126-128.	10.1	11
192	The prevalence of oral anticoagulation in patients with atrial fibrillation in Portugal: Systematic review and meta-analysis of observational studies. <i>Revista Portuguesa De Cardiologia (English)</i> 11(5):50-59	1.0	11
193	The risk of infection with new oral anticoagulants: A meta-analysis. <i>International Journal of Cardiology</i> , 2014, 172, 267-268.	1.7	11
194	Prevalence of Parkinson's disease: a population-based study in Portugal. <i>European Journal of Neurology</i> , 2017, 24, 748-750.	3.3	11
195	Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 649-659.	2.8	11
196	Critical appraisal of clinical trials in multiple system atrophy: Toward better quality. <i>Movement Disorders</i> , 2017, 32, 1356-1364.	3.9	11
197	Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo?. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 16-19.	2.2	11
198	The incidence of thrombotic events with idarucizumab and andexanet alfa: A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2020, 196, 291-296.	1.7	11

#	ARTICLE	IF	CITATIONS
199	Contingent negative variation: a biomarker of abnormal attention in functional movement disorders. <i>European Journal of Neurology</i> , 2020, 27, 985-994.	3.3	11
200	Validation of quantitative gait analysis systems for Parkinson's disease for use in supervised and unsupervised environments. <i>BMC Neurology</i> , 2021, 21, 331.	1.8	11
201	Automatic Detection of Parkinson's Disease: An Experimental Analysis of Common Speech Production Tasks Used for Diagnosis. <i>Lecture Notes in Computer Science</i> , 2017, , 411-419.	1.3	11
202	Pimavanserin for the treatment of Parkinson's disease psychosis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2115-2124.	1.8	10
203	Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients. <i>Parkinsonism and Related Disorders</i> , 2021, 87, 25-31.	2.2	10
204	Has levodopa-induced neuropathy been reported in Parkinson's disease clinical trials?. <i>Movement Disorders</i> , 2011, 26, 1966-1967.	3.9	9
205	Referral to rehabilitation in Parkinson's disease: who, when and to what end?. <i>Arquivos De Neuro-Psiquiatria</i> , 2013, 71, 967-972.	0.8	9
206	Delayed Parkinsonism after acute chorea due to non-ketotic hyperglycemia. <i>Journal of the Neurological Sciences</i> , 2015, 354, 116-117.	0.6	9
207	Resting and Reemergent Tongue Tremor as Presenting Symptoms of Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 273-274.	1.5	9
208	Quality and reporting of guidelines on the diagnosis and management of dystonia. <i>European Journal of Neurology</i> , 2018, 25, 275-283.	3.3	9
209	Is lowering stimulation frequency a feasible option for subthalamic deep brain stimulation in Parkinson's disease patients with dysarthria?. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 242-248.	2.2	9
210	Swimming is Compromised in Parkinson's Disease Patients. <i>Movement Disorders</i> , 2020, 35, 365-369.	3.9	9
211	Feasibility of a Mobile-Based System for Unsupervised Monitoring in Parkinson's Disease. <i>Sensors</i> , 2021, 21, 4972.	3.8	9
212	Sneeze as a precipitating factor of cerebral venous thrombosis. <i>European Journal of Neurology</i> , 2007, 14, e7-e8.	3.3	8
213	Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: Identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants. <i>Parkinsonism and Related Disorders</i> , 2013, 19, 897-900.	2.2	8
214	Tolerability and Acceptability of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation: Systematic Review and Meta-Analysis. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 259-265.	2.2	8
215	The era of the novel oral anticoagulants in Portugal. <i>Revista Portuguesa De Cardiologia (English)</i> Tj ETQq1 1 0.784314 rgBT /Qverlock 0.2 8	0.2	8
216	Comparison of Huntington's Disease in Europe and North America. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 358-367.	1.5	8

#	ARTICLE	IF	CITATIONS
217	A critique of the fragility index. <i>Lancet Oncology</i> , The, 2019, 20, e553.	10.7	8
218	Cardiovascular events reported in randomized controlled trials in restless legs syndrome. <i>Sleep Medicine</i> , 2020, 65, 13-17.	1.6	8
219	Patients and Health Professional's Perspective of Functional Mobility in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 575811.	2.4	8
220	Analysis of clinical and methodological characteristics of early COVID-19 treatment clinical trials: so much work, so many lost opportunities. <i>BMC Medical Research Methodology</i> , 2021, 21, 42.	3.1	8
221	The Parkinsonâ€™s Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinsonâ€™s Disease in Patients and their Carers. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1309-1323.	2.8	8
222	Opicapone versus placebo in the treatment of Parkinsonâ€™s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone) Tj ETQq0 0.8gBT /Overlock 10 T	0.8	7
223	Strong nocebo effect in amyotrophic lateral sclerosis trials might mask conclusions. <i>Lancet Neurology</i> , The, 2018, 17, 842.	10.2	7
224	Recommendations and levels of evidence in the guidelines of the European Society of Cardiology: current scenario and time trends. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 122-124.	3.0	7
225	A Standardized <sc>MR</sc> Imaging Protocol for Parkinsonism. <i>Movement Disorders</i> , 2020, 35, 1745-1750.	3.9	7
226	Outcome Measures for Evaluating the Effect of a Multidisciplinary Intervention on Axial Symptoms of Parkinson's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 328.	2.4	7
227	Cardiovascular Adverse Events Reported in Placebo Arm of Randomized Controlled Trials in Parkinsonâ€™s Disease. <i>Journal of Parkinson's Disease</i> , 2020, 10, 641-651.	2.8	7
228	Parkinsonâ€™s Disease Drug Development Since 1999: A Story of Repurposing and Relative Success. <i>Journal of Parkinson's Disease</i> , 2021, 11, 421-429.	2.8	7
229	Risk of SARSâ€CoVâ€2 Infection and COVIDâ€19 Severity Associated With Exposure to Nonsteroidal Antiâ€Inflammatory Drugs: Systematic Review and Metaâ€Analysis. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 1521-1533.	2.0	7
230	The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Post-hoc Analysis of BIPARK-I and -II. <i>Frontiers in Neurology</i> , 2021, 12, 754016.	2.4	7
231	Postural abnormalities in Asian and Caucasian Parkinson's disease patients: A multicenter study. <i>Parkinsonism and Related Disorders</i> , 2022, 97, 91-98.	2.2	7
232	Usefulness of OSLEP test in Parkinsonâ€™s disease. <i>Sleep Medicine</i> , 2013, 14, 297-298.	1.6	6
233	Pericardial bleeding risk with non-vitamin K oral anticoagulants: A meta-analysis. <i>International Journal of Cardiology</i> , 2015, 182, 187-188.	1.7	6
234	A peripheral pathway to restless legs syndrome? Clues from familial amyloid polyneuropathy. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1465-1468.	2.2	6

#	ARTICLE	IF	CITATIONS
235	The "Long and Winding Road" of the Disease—Modifying Effects of Levodopa Has Not Ended Yet. <i>Movement Disorders</i> , 2020, 35, 397-399.	3.9	6
236	Botulinum toxin type A therapy for hemifacial spasm. <i>The Cochrane Library</i> , 2020, 2020, CD004899.	2.8	6
237	Optimizing Treatment in Undertreated Late-Stage Parkinsonism: A Pragmatic Randomized Trial. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1171-1184.	2.8	6
238	Feasibility and Safety of Telerehabilitation for Physiotherapy Interventions in Movement Disorders Patients. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 1144-1147.	1.5	6
239	Adjunctive entacapone therapy increases risk of dyskinesia. <i>Nature Reviews Neurology</i> , 2010, 6, 590-591.	10.1	5
240	Pharmacotherapy in Parkinson's disease: case studies. <i>Therapeutic Advances in Neurological Disorders</i> , 2010, 3, 117-126.	3.5	5
241	Reluctance to start medication for Parkinson's disease: A mutual misunderstanding by patients and physicians. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 608-612.	2.2	5
242	Safety of non-vitamin K antagonist oral anticoagulants - coronary risks. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 731-740.	2.4	5
243	Neuromelanin magnetic resonance imaging of the substantia nigra in <i>LRRK2</i> -related Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1331-1333.	3.9	5
244	Suspected adverse drug reaction reports with oral anticoagulants in Portugal: a pharmacovigilance study. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 339-345.	2.4	5
245	Psychosocial impact of Parkinson's disease-associated dysarthria: Cross-cultural adaptation and validation of the Dysarthria Impact Profile into European Portuguese. <i>Geriatrics and Gerontology International</i> , 2018, 18, 767-774.	1.5	5
246	Reporting and methodological quality of clinical trials on exercise therapy for Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 69, 150-156.	2.2	5
247	The Role of Architecture and Design in the Management of Parkinson's Disease: A Systematic Review. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1301-1314.	2.8	5
248	Cross-cultural adaptation and validation of the Swallowing Disturbance Questionnaire and the Sialorrhea Clinical Scale in Portuguese patients with Parkinson's disease. <i>Logopedics Phoniatrics Vocology</i> , 2021, 46, 163-170.	1.0	5
249	Strategies to minimize placebo effects in research investigations. <i>International Review of Neurobiology</i> , 2020, 153, 49-70.	2.0	5
250	Speech intelligibility of Parkinson's disease patients evaluated by different groups of healthcare professionals and naïve listeners. <i>Logopedics Phoniatrics Vocology</i> , 2021, 46, 141-147.	1.0	5
251	Safety and tolerability of sacubitril-valsartan: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 577-588.	2.4	5
252	Does Parkinson's Disease Increase the Risk of Atrial Fibrillation? Insights From Electrocardiogram and Risk Scores From a Case-Control Study. <i>Frontiers in Neurology</i> , 2021, 12, 633900.	2.4	5

#	ARTICLE	IF	CITATIONS
253	Profile of cognitive impairment in late-stage Parkinson's disease. <i>Brain and Behavior</i> , 2022, 12, e32537.	2.2	5
254	Evidence-based medicine (EBM) applied to Parkinson's disease treatment. <i>Parkinsonism and Related Disorders</i> , 2002, 9, 7-13.	2.2	4
255	Net clinical benefit outcome should be standardized in trials evaluating antithrombotic drugs: The example of NOACs in atrial fibrillation. <i>International Journal of Cardiology</i> , 2014, 174, 405-406.	1.7	4
256	Reply to letter: Does Parkinson's disease increase the risk of cardiovascular events? A systematic review and meta-analysis. <i>European Journal of Neurology</i> , 2020, 27, e12.	3.3	4
257	Should the Energy Contribution of Commercial Thickeners Be Considered in the Nutrition Plan of Patients With Dysphagia?. <i>Nutrition in Clinical Practice</i> , 2020, 35, 649-654.	2.4	4
258	Inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinson's disease. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 85-101.	3.1	4
259	Unsupervised Walking Activity Assessment Reveals COVID-19 Impact on Parkinson's Disease Patients. <i>Movement Disorders</i> , 2021, 36, 531-532.	3.9	4
260	Kinematic and Clinical Outcomes to Evaluate the Efficacy of a Multidisciplinary Intervention on Functional Mobility in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 637620.	2.4	4
261	Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease. <i>Movement Disorders</i> , 2021, 36, 1964-1967.	3.9	4
262	Cardiovascular and cerebrovascular risk markers in Parkinson's disease: Results from a case-control study. <i>European Journal of Neurology</i> , 2021, 28, 2669-2679.	3.3	4
263	(Dys)Prosody in Parkinson's Disease: Effects of Medication and Disease Duration on Intonation and Prosodic Phrasing. <i>Brain Sciences</i> , 2021, 11, 1100.	2.3	4
264	High frequency of psychosis in late-stage Parkinson's disease. <i>Clinical Parkinsonism & Related Disorders</i> , 2021, 5, 100119.	0.9	4
265	The Interaction between HLA-DRB1 and Smoking in Parkinson's Disease Revisited. <i>Movement Disorders</i> , 2022, 37, 1929-1937.	3.9	4
266	Wearing-off phenomena and levodopa-induced dyskinesias in posttraumatic hemiparkinsonism. <i>Movement Disorders</i> , 2013, 28, 1212-1214.	3.9	3
267	Levodopa response in later stages of Parkinson's disease: A case-control study. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 160-162.	2.2	3
268	Potential drug-drug interactions in acute poisonings managed in the intensive care unit: Occurrence, risk factors and relationship to patient severity on admission. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2022, 130, 337-345.	2.5	3
269	Adverse Events of Physiotherapy Interventions in Parkinsonian Patients. <i>Movement Disorders Clinical Practice</i> , 2022, 9, 744-750.	1.5	3
270	End of OSLE Test Sessions in Parkinson's Disease do not Correspond to True Sleep Onset: Results from an Exploratory Study. <i>Frontiers in Neurology</i> , 2015, 6, 200.	2.4	2

#	ARTICLE	IF	CITATIONS
271	Suicidal behaviors are very rare in antiparkinsonian drug trials. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1008-1009.	2.2	2
272	One-year follow-up of opicapone's efficacy and safety in patients with Parkinson's disease and motor fluctuations (BIPARK I). <i>Parkinsonism and Related Disorders</i> , 2016, 22, e100.	2.2	2
273	Comments on: "Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease" a randomized controlled trial. <i>European Journal of Neurology</i> , 2018, 25, e4.	3.3	2
274	The placebo response in Parkinson's disease and other movement disorders. <i>Movement Disorders</i> , 2018, 33, 1193-1194.	3.9	2
275	Tapentadol Prevents Motor Impairments in a Mouse Model of Dyskinesia. <i>Neuroscience</i> , 2020, 424, 58-71.	2.3	2
276	Terminal Pro-B-type Natriuretic Peptide Levels in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1886-1887.	3.9	2
277	Neuromelanin Magnetic Resonance Imaging of the Substantia Nigra in Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2020, 9, 143-148.	1.9	2
278	Clinical Diagnostic Criteria Have a High Impact on the Frequency of Dementia in Late-Stage Parkinson's Disease. <i>Frontiers in Neurology</i> , 2021, 12, 652424.	2.4	2
279	Anticoagulation therapy in patients with post-operative atrial fibrillation: Systematic review with meta-analysis. <i>Vascular Pharmacology</i> , 2022, 142, 106929.	2.1	2
280	Frequency and Characteristics of Psychosis in Parkinson's Disease: A Systematic Review and Meta-Analysis. <i>Journal of Parkinson's Disease</i> , 2022, 12, 85-94.	2.8	2
281	Low risk of haematomas with intramuscular vaccines in anticoagulated patients: a systematic review with meta-analysis. <i>Thrombosis Journal</i> , 2022, 20, 9.	2.1	2
282	The sham effect of invasive interventions in chronic coronary syndromes: a systematic review and meta-analysis. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 223.	1.7	2
283	Assessment Tools to Evaluate Motor Function in People with Dementia: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2022, 89, 13-24.	2.6	2
284	Movement disorders in renal diseases. , 2014, , 172-188.		1
285	Glaucoma Surgery and Anticoagulant Therapy"Reply. <i>JAMA Ophthalmology</i> , 2015, 133, 1365.	2.5	1
286	Caffeine and Neuroprotection in Parkinson's Disease. <i>Current Topics in Neurotoxicity</i> , 2015, , 233-272.	0.4	1
287	Musician's Dystonia as the Initial Presentation of Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016, 3, 624-625.	1.5	1
288	Association Between Body Mass Index and Parkinson Disease. <i>JAMA Neurology</i> , 2016, 73, 891.	9.0	1

#	ARTICLE	IF	CITATIONS
289	A rare cause of orofacial dyskinesias. <i>Parkinsonism and Related Disorders</i> , 2018, 50, 122-123.	2.2	1
290	Information Sources and Decision-Making in Neurosurgery: Results of a Survey of Members of the Brazilian Neurosurgery Society. <i>Brazilian Neurosurgery</i> , 2018, 37, 081-087.	0.1	1
291	Feasibility of using risk prompts to prevent falls, dehydration and pulmonary aspiration in nursing homes: a clinical study protocol. <i>Pilot and Feasibility Studies</i> , 2018, 4, 39.	1.2	1
292	Aspirin for Primary Cardiovascular Prevention in Patients with Family History of Cardiovascular Disease: Meta-analysis. <i>Cardiovascular Drugs and Therapy</i> , 2021, 35, 871-873.	2.6	1
293	Botulinum toxin type A versus anticholinergics for cervical dystonia. <i>The Cochrane Library</i> , 2021, 2021, CD004312.	2.8	1
294	Antithrombotic Therapy Recommendations in the European Society of Cardiology Guidelines: How Robust Are the Randomized Controlled Trials Underpinning Them?. <i>TH Open</i> , 2021, 05, e125-e133.	1.4	1
295	Clinical Utility of Opicapone in the Management of Parkinson's Disease: A Short Review on Emerging Data and Place in Therapy. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2021, Volume 11, 29-40.	1.3	1
296	Epidemiology of Levodopa-Induced Dyskinesia. , 2014, , 33-50.		1
297	The Natural History of Parkinson's Disease. , 2017, , 129-137.		1
298	Clinical Trials for in Parkinson's. <i>Neuromethods</i> , 2021, , 109-135.	0.3	1
299	Essential tremor. <i>Clinical Evidence</i> , 2004, , 1674-86.	0.2	1
300	Neuroimaging cerebrovascular biomarkers in Parkinson's disease. <i>Neuroradiology Journal</i> , 2022, 35, 490-496.	1.2	1
301	Systematic reviews and meta-analysis published in indexed Portuguese medical journals: time trends and critical appraisal. <i>BMC Medical Research Methodology</i> , 2022, 22, 105.	3.1	1
302	Smartphone-Based Body Location-Independent Functional Mobility Analysis in Patients with Parkinson's Disease: A Step towards Precise Medicine. <i>Journal of Personalized Medicine</i> , 2022, 12, 826.	2.5	1
303	Therapeutic interventions for sleep disorders in Parkinson's disease. <i>The Cochrane Library</i> , 0, , .	2.8	0
304	Piribedil versus levodopa in early Parkinson's disease. <i>The Cochrane Library</i> , 2007, , .	2.8	0
305	Therapeutic interventions for daytime somnolence in Parkinson's disease. <i>The Cochrane Library</i> , 2007, , .	2.8	0
306	A multimodal approach to physical therapy in Parkinson's disease: Optimizing strategies. <i>Movement Disorders</i> , 2009, 24, 946-946.	3.9	0

#	ARTICLE	IF	CITATIONS
307	Warfarin, acetylsalicylic acid and risk of incident atrial fibrillation in patients with heart failure and sinus rhythm: A meta-analysis. <i>International Journal of Cardiology</i> , 2013, 168, 4842-4843.	1.7	0
308	Spinal Cord Lesion by Minor Trauma as an Early Sign of Multiple System Atrophy. <i>Frontiers in Neurology</i> , 2016, 7, 33.	2.4	0
309	Reply to letter: Exogenous melatonin for Parkinson's disease: "Waking up" to the need for further trials. <i>Parkinsonism and Related Disorders</i> , 2016, 29, 123-124.	2.2	0
310	Comparison of huntington's disease in Europe and North America. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A68.4-A69.	1.9	0
311	Upcoming international guidelines in huntington's disease. , 2018, , .		0
312	Erratum - Information Sources and Decision-Making in Neurosurgery: Results of a Survey of Members of the Brazilian Neurosurgery Society. <i>Brazilian Neurosurgery</i> , 2018, 37, 162-162.	0.1	0
313	Physician perception versus true efficacy of tetrabenazine for Huntington's disease. <i>Current Medical Research and Opinion</i> , 2018, 34, 1537-1538.	1.9	0
314	The risks of converting post-hoc findings into primary outcomes in subsequent trials. <i>Annals of Translational Medicine</i> , 2019, 7, S337-S337.	1.7	0
315	Are Happiness and Well-being the Same Outcome?. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1787-1788.	2.8	0
316	Reply to the letter "We never speak about sudden unexpected death in Parkinson's disease". <i>European Journal of Neurology</i> , 2020, 27, e29.	3.3	0
317	Magnetic resonance imaging visual analysis of neuromelanin and nigrosome-1 for the assessment of striatonigral disfunction in huntington's disease. , 2021, , .		0
318	Piribedil for symptomatic management of Parkinson's disease. <i>The Cochrane Library</i> , 0, , .	2.8	0
319	Piribedil for levodopa-induced complications in Parkinson's disease. <i>The Cochrane Library</i> , 0, , .	2.8	0
320	Medical Treatment of Parkinson's Disease. , 2017, , 139-156.		0
321	Rationale on the decision-making process for opicapone's bedtime regimen in Parkinson's disease. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO2-14-36.	0.0	0
322	Reader response: Beware of deep water after subthalamic deep brain stimulation. <i>Neurology</i> , 2020, 95, 758-759.	1.1	0
323	Effect of oxygen supply on mortality in acute ST-elevation myocardial infarction: systematic review and meta-analysis. <i>European Journal of Emergency Medicine</i> , 2021, 28, 11-18.	1.1	0
324	Essential tremor. <i>Clinical Evidence</i> , 2003, , 1421-31.	0.2	0